Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Transcript
With therapies like CAR T-cell therapy entering the market, will reimbursement present significant challenges to providers?
CAR T—I was talking to my doctor about this because I’m not clinical and I want to make sure I got her opinion, and she said, with CAR T, the insurers are not paying for it right now, we don’t know what’s going to happen, it really should be happening in a hospital, but if you’re not partnering with your hospital and you’re trying to do it in an independent practice, it’s not going to be easy.
I think from a cost perspective, we don’t know what the market’s going to do, we don’t know what the payers are going to do. We do know that we can’t get that medication, we can’t get CAR T therapies very easily in community oncology. We can’t even get it from the [group purchasing organization] we currently have. You have to go through a certain specialty, and it is very costly. So, I think that’s remaining to be seen. It’s something that we’ll have to kind of see how it goes.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More